Specific Mycobacterium tuberculosis T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy

Irene Latorre, Neus Altet, Malú De Souza-Galvão, Joan Ruiz-Manzano, Alicia Lacoma, Cristina Prat, Miguel Pérez, Vicente Ausina, Jose Domínguez

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Background: Recently, a selection of HLA class II-restricted epitopes of ESAT-6 and CFP-10 Mycobacterium tuberculosis proteins from the region of difference (RD) 1 have been described. We have evaluated the host interferon-gamma (IFN-γ) T cell response to these RD1 selected peptides at the beginning and during anti-tuberculosis therapy. Methods: We studied 29 pulmonary TB patients enrolled at the beginning of treatment and 24 enrolled during treatment. We performed T-SPOT.TB and ELISPOT with RD1 selected peptides. Results: Patients included at the beginning of treatment responded producing IFN-γ after antigen stimulation in 89.7% by means of T-SPOT.TB and 79.3% by means of RD1 selected ELISPOT. In contrast, for patients included during treatment the percentages were 87.5% and 25%, respectively. Differences in sensitivities between patients evaluated at the beginning and during treatment were only significant for RD1 selected ELISPOT (p < 0.0001). Conclusions: The host immune response to RD1 selected peptides is lower than to T-SPOT.TB during therapy. Immunological assays based on RD1 selected peptides may be useful tools for studying the immune response during anti-tuberculosis therapy. © 2012 Informa Healthcare.
Original languageEnglish
Pages (from-to)161-167
JournalScandinavian Journal of Infectious Diseases
Volume44
Issue number3
DOIs
Publication statusPublished - 1 Mar 2012

Keywords

  • IFN-γ assays
  • Immune response
  • Monitoring anti-TB treatment
  • Mycobacterium tuberculosis
  • RD1 selected peptides

Fingerprint

Dive into the research topics of 'Specific Mycobacterium tuberculosis T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy'. Together they form a unique fingerprint.

Cite this